ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNG Synairgen Plc

4.52
-0.235 (-4.94%)
24 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.235 -4.94% 4.52 4.35 4.69 4.75 4.36 4.75 212,429 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.50 9.58M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.76p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.58 million. Synairgen has a price to earnings ratio (PE ratio) of -0.50.

Synairgen Share Discussion Threads

Showing 5701 to 5724 of 99175 messages
Chat Pages: Latest  235  234  233  232  231  230  229  228  227  226  225  224  Older
DateSubjectAuthorDiscuss
30/4/2020
12:42
This and STX flying at last. Hallelujah !
peachie 74
30/4/2020
12:42
Sensational news, must be showing very positive effects for a new home trial! Should be at least £1 when you think this is a treatment rather than just a test...
74tom
30/4/2020
12:41
An actual RNS is massive!!!!!!!!
slinkyj
30/4/2020
12:40
70p offered now
bmnsa
30/4/2020
12:39
So we have to wait for what looks like will be good news rather than worry at the prospect it may not be.would say more tilted in favour of a good readout now from the trial.
So materially derisked I would say.

fidra
30/4/2020
12:37
NHS obviously likes sng001 two rampy research notes in two days
bobaxe1
30/4/2020
12:36
Amazing rise. Overall good news but a June readout is I guess the only fly in the ointment. I was expecting it earlier.
nobbygnome
30/4/2020
12:36
Tidy £800 profit today. I'm off to cut the grass. Gla
northern66
30/4/2020
12:36
The ten percenters will take their profit but this is major news.
rafboy
30/4/2020
12:31
Needs to break 72p
d1nga
30/4/2020
12:29
Has this push got legs at last???
mostro
30/4/2020
12:29
Like I said earlier about potential holders waiting for strong moves north.Think we will see a snowball effect now.Also trades are increasing in size.
cambradjones
30/4/2020
12:29
Bought for 53p earlier
bmnsa
30/4/2020
12:28
I'm bid 63.55
bmnsa
30/4/2020
12:26
135k just bought 🙂
makendon
30/4/2020
12:21
I would say that’s pretty positive.you don’t extend if it is not working,and they now think taking it earlier could work in the home,which would result in less hospitalisation numbers.

Win win

fidra
30/4/2020
12:20
Perhaps now we will head for the 1 pound?
slinkyj
30/4/2020
12:19
Good that the results from both arms, hospital and home, will be announced seperately. There was a concern that the hospital ones would be held over until home had completed. So still on track for June result and maybe July for home treatment??

Excellent news.

pdt
30/4/2020
12:17
Market going to wake up soon. Ticking all boxes
bobaxe1
30/4/2020
12:16
That is really great news.
rolaw1
30/4/2020
12:15
Anna McDonald 'The fund manager also discusses in the podcast how she has invested in Synairgen (SNG:AIM) and other stocks looking to treat coronavirus or help pharma companies to find a vaccine.'
slinkyj
30/4/2020
12:15
These dips are catching people out now. Getting locked out.
peachie 74
30/4/2020
12:14
75% recruited good progress on schedule for completing the hospital trial, exciting addition with home trial and results June as expected! All positive.
crookie3634
30/4/2020
12:13
Approval received to extend SG016 clinical study of SNG001 in COVID-19 to initiate patients in the home environment

Southampton, UK - 30 April 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has received approvals to extend the SG016 trial to patients with SARS-CoV-2 in the home environment. The objective is to initiate dosing with SNG001 (or placebo) earlier in the infection cycle, and before severe lower respiratory tract symptoms have developed. In due course, details of the design, implementation and timing of this novel study will be disclosed more fully.


The treatment of patients in the hospital setting in the SG016 study is progressing well, with more than 75 patients out of the target 100 now dosed with Synairgen's wholly-owned drug SNG001 or placebo. Results from this part of the study are still expected in June 2020

euclid5
Chat Pages: Latest  235  234  233  232  231  230  229  228  227  226  225  224  Older

Your Recent History

Delayed Upgrade Clock